Time filter

Source Type

Shenyang, China

Shenyang Pharmaceutical University is a university in Shenyang, Liaoning, China. It is the first research institutes in pharmaceutical science in China.Shenyang Pharmaceutical University has historical traditions that have brought it to prominence as one of two comprehensive pharmaceutical universities in all of China. The university started at Ruijin in the Jiangxi in 1931 and moved to its present location on the banks of the Hun River in Shenyang, Liaoning in 1949. SPU has developed into a multidisciplinary, multilevel and multiform institute of higher learning, covering wide and diverse majors within the domain of pharmaceutical study. It consists of the schools of Pharmacy, Pharmaceutical engineering, Traditional Chinese Medicines, Business Administration, Basic Courses, and Adult Education. SPU has been authorized to confer master's and doctor's degrees and to enroll students from Hong Kong, Macau, Taiwan, as well as other countries. SPU has resources that facilitate learning: The Institute of Material Medicine; The Institute of Pharmaceutical Education of Higher Learning; The Computer Center; The Audio-visual Education Program Center; The Center of Instrumental Analysis; The Botanical Garden of Medicinal Herbs, and a subsidiary pharmaceutical factory. SPU has a staff of 1,111, among them there are 394 full-time teachers. The student population has grown to more than 7,000. There is one academician of the Chinese Academy of Engineering, over 182 professors and associate professors .More than 3,000 academic papers have been published by SPU academics on research toward recommended dosages of pharmaceutical preparations, polyphase liposomes and solid preparations, on chemical and active components of traditional Chinese medicines and natural drugs, on the distinction and properties of chemical models of traditional Chinese medicines and the study of their quality control. All of this scientific exploration is at the forefront of research in China. In recent years, numerous mutually beneficial collaborative efforts have come to fruition between the University's academics and all levels of government: city, province, and state. Wikipedia.

Shi K.,Shenyang Pharmaceutical University
Pharmaceutical research | Year: 2013

To make a comparative study on sustained delivery performance of rhIFN with random amorphous and spherical crystal-like ordered self-assemblies. The rhIFN self-assemblies were identified in batch crystallization mode. Physico-chemical characteristics were compared, including morphology, XRD, FTIR, CD, biological potency, the dissolution behaviors in vitro and plasma pharmacokinetics in vivo. Moreover, molecular simulation was performed to better understand their binding site and mode. Here, we suggest that random amorphous and spherical ordered self-assemblies allow for long action without new molecular entities generation or carriers employed. By manipulating supersaturation, the ordered aggregates were self-organized at high concentration of Zn(II) (>100 mM) in pH 5.5-6.0, which was the first time that spherical semi-crystals of rhIFN can act as a depot source for the sustained delivery of biologically active proteins. The secondary structure and biological potency of rhIFN were unchanged after aggregation. Compared with that of the native rhIFN, both self-assemblies exhibited slower absorption and extended elimination profiles after s.c. administration, which were characterized as 4.75 ± 0.82 h and 10.58 ± 1.86 h of terminal half-life for random amorphous and spherical ordered self-assemblies, respectively. The work described here demonstrates the possibility of self-assemblies of biomacromolecules for controllable release application of therapeutic proteins. Source

Li X.,Shenyang Pharmaceutical University
International journal of nanomedicine | Year: 2011

The purpose of this study was to develop folate-poly (PEG-cyanoacrylate-co-cholesteryl cyanoacrylate) (FA-PEG-PCHL)-modified freeze-dried liposomes for targeted chemotherapy using docetaxel as a model drug. FA-PEG-PCHL was synthesized and its cytotoxicity was evaluated by CCK-8 assay in L929. Docetaxel-loaded liposomes modified by FA-PEG-PCHL were prepared by an organic solvent injection method and lyophilized to obtain freeze-dried FA-PEG-PCHL-docetaxel liposomes (FA-PDCT-L). Two carcinoma cell lines (MCF-7 and A-549 cells) were cultured with docetaxel solution, conventional docetaxel-loaded liposomes, or FA-PDCT-L, and the cytotoxicity and apoptosis was evaluated for each preparation. The uptake of the docetaxel preparations into MCF-7 cells was studied by confocal laser scanning microscopy. Liquid chromatography-mass spectrometry was used to study the pharmacokinetics and tissue distribution characteristics of the preparations. The existence of an enlarged fixed aqueous layer on the surface of the liposomes was affirmed by zeta potential analysis. The entrapment efficiency and particle size distribution were almost the same as those of docetaxel-loaded liposomes. The drug release profile showed that the release rate was faster at higher molecular weight of the polymer. Compared with docetaxel solution and docetaxel-loaded liposomes, FA-PDCT-L demonstrated the strongest cytotoxicity against two carcinoma cell lines, the greatest intracellular uptake especially in the nucleus, as well as the most powerful apoptotic efficacy. In pharmacokinetic studies, the area under the plasma concentration-time curve of FA-PDCT-L was increased 3.82 and 6.23 times in comparison with the values for the docetaxel-loaded liposomes and docetaxel solution, respectively. Meanwhile, a lower concentration of docetaxel was observed for FA-PDCT-L in the liver and spleen, and a significantly higher concentration of FA-PDCT-L in tumors suggested that the presence of FA-PEG-PCHL on the liposomes resulted in greater accumulation of the drug in tumor tissue. Liposomes modified by FA-PEG-PCHL could be one of the promising suspensions for the delivery of antitumor drugs in cancer. Source

Lei Y.,Shenyang Pharmaceutical University
International journal of nanomedicine | Year: 2011

The objective of this study was to evaluate fluid-bed coating as a new technique to prepare a pellet-based solid self-nanoemulsifying drug delivery system (SNEDDS) using cyclosporin A as a model of a poorly water-soluble drug. The rationale of this technique was to entrap a Liquid SNEDDS in the matrix of the coating material, polyvinylpyrrolidone K30, by fluid-bed coating. Pseudoternary phase diagrams were used to screen the liquid SNEDDS formulations. The optimal formulation was composed of Labrafil M(®) 1944 CS, Transcutol P(®), and Cremophor(®) EL in a ratio of 9:14:7. To prepare solid SNEDDS pellets, liquid SNEDDS was first dispersed in an aqueous solution of polyvinylpyrrolidone and then sprayed onto the surface of non-pareil pellets. Upon evaporation of water, polyvinylpyrrolidone precipitated and formed tight films to entrap the liquid SNEDDS. Visual observation and scanning electron microscopic analysis confirmed good appearance of the solid SNEDDS pellets. Our results indicated that up to 40% of the liquid SNEDDS could be entrapped in the coating layer. Powder x-ray diffraction analysis confirmed nonexistence of crystalline cyclosporin A in the formulation. Solid SNEDDS pellets showed a slower redispersion rate than the liquid SNEDDS. An increase in the total liquid SNEDDS loading led to faster redispersion, whereas increased coating weight (up to 400%) significantly decreased the redispersion rate. Both cyclosporin A loading and protective coating with 5% polyvinylpyrrolidone K30 did not significantly affect the redispersion rate. It is concluded that fluid-bed coating is a new technique with considerable potential for preparation of pellet-based solid SNEDDS formulations. Source

The present invention belongs to the field of medicinal technique, specifically relates to nitrogen-containing heterocyclic ring-substituted dihydroartemisinin derivatives and their optical isomers according to formula I or II; wherein substituent X, Y, r, R

Zhao L.,Shenyang Pharmaceutical University | Li F.,Shenyang Pharmaceutical University
TrAC - Trends in Analytical Chemistry | Year: 2014

The combination of ultra-high-performance liquid chromatography and mass spectrometry (UHPLC-MS) offers advantages of high speed, resolution and sensitivity. With these technological advantages, UHPLC-MS has been widely applied to areas of bioanalysis, one of which involves stages of drug discovery and development. This article aims to provide a comprehensive, up-to-date overview of published literature on UHPLC-MS strategies and applications in bioanalyses related to pharmacokinetics and drug metabolism, to give the readers from academia and industry sufficient information about these aspects. © 2014 Elsevier B.V. Source

Discover hidden collaborations